| Popis: |
Prognosis in certain types of cancers still poor like in glioblastoma, some types of leukemia & lung cancer. Royal Jelly (RJ) chemical investigations started in 1960s and Major Royal Jelly proteins (MRJPs)were first reported in 1992. Later on, in 2006 after bee genome publication, nine different types of MRJPs were confirmed. Apisimin a new peptide found in RJ was discovered in 2002, and in 2004 Jelleines peptides group were also reported in RJ. While Apisimin and Jellein 4 of not known biological activities recorded, Jellein 1, 2 &3 peptides showed antibacterial effect, antifungal effects, mast cell degranulation activity and hemolysis. However, nobody used Jelleins, Apisimin derivatives or both in a trial to treat cancer. Here we show new significant cancer inhibitions for a combination of Apisimin derivatives and modified Jelleins (with a change of few amino acids to d-form). In vivo studies, using a combination of peptide J1d (modified Jellein 1)and Ap3d( peptide contains 8 amino acids from c-terminal of Apisimin) in one group and a peptide K2( synthetic peptide consists of Ap3d + J1d) in another group in U-87 nude mice, we got significant inhibitions in both groups. In another studies, using K2 peptide in one group and K3 peptide( synthetic peptide consists of Ap4d+ J2d) in another group versus C1498 and LLC syngeneic models, we also got significant inhibitions. We got no effect when using any Jelleins as well as with any Apisimin derivatives. Our results demonstrate the effectiveness of using Apisimin derivatives peptides and modified Jelleins simultaneously in cancers. |
